ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 485

Incidence of Clinical and Serological Lupus-like Disease during Anti-Tnfα-Treatment – a Two-Year Prospective Study in an Interdisciplinary Patient Cohort

Simon Julius Winkelmann1, Rainald A. Zeuner1, Dörte Schuldt1, Johannes Bethge1, Ulrich Mrowietz2, Matthias Laudes1, Stefan Schreiber1 and Johann Schroeder1, 11st Medical Dept, University of Kiel, Kiel, Germany, 2Dermatology, Univ Schleswig-Holstein, Kiel, Germany

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: etanercept, inflammatory bowel disease (IBD), infliximab and rheumatoid arthritis (RA), Lupus

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: TNFα-Inhibitors are the most widely used biological agents in rheumatic conditions or other chronic inflammatory diseases. Over the last ten years, the occurrence of lupus-like disease and the induction of antinuclear antibodies have been observed in more than 800 individuals receiving anti-TNFα-treatment worldwide. However, the exact incidence of serological changes and the frequency of associated clinical manifestations are unknown.

Methods: We conducted a single center, interdisciplinary prospective study on patients with RA, spondyloarthropathies and inflammatory bowel diseases who were elected for anti-TNFα-therapy as their first biological treatment. Clinical and serological parameters were collected before the first application and thereafter at six-monthly intervals. The evaluation included a clinical questionnaire and serological testing for ANA, dsDNA-antibodies and ANCA. We calculated the incidence rates based upon duration of drug exposure. The odds ratios within the subgroups were adjusted to the diagnosis or the compound with the lowest event rate, respectively.

Results: Between January 2011 and February 2014, 223 patients entered the study. The underlying diseases of these patients were RA (68), spondyloarthropathies (67), inflammatory bowel disease (84) and JIA (4). During the follow-up, 318 serum samples were collected, 117 of these were allotted to week 26, 89 to week 52, 51 to week 78 and 61 to week 104 of follow-up. – During the entire observation period, there was a continuous rise in ANA-titers and in the concentration of dsDNA-antibodies. The proportion of samples tested positive for ANA increased from 20 or 9.0% at baseline to 21 out of 56 or 37.5% respectively at week 104 (p=0.001). The proportion of samples with dsDNA-antibodies above the normal range (20 IU/ml) rose from none at baseline to 16 of 49 or 32.7% at the two year evaluation (p=0.0002), the average anti-dsDNA value increasing from 5.6 IU/ml to 18.5 IU/ml (p=0.004). These results were confirmed by a crithidia luciliae assay in 51.4% of these cases. 5 individuals or 2.5% of the study population additionally developed musculoskeletal symptoms assessed as lupus-like disease. These events required temporary termination of anti-TNFαtreatment and the application of corticosteroids. – When analyzing the impact of the various biologics and the co-medication, the highest seroconversion rate was observed in patients receiving infliximab (46.1%), followed by adalimumab (15.6%), certolizumab (8.2%) and etanercept (6.1%). In patients being treated with concomitant MTX (only rheumatic conditions were considered), the risk was lower (odds ratio 0.87) than in patients without MTX.

Conclusion: The present data confirm the capability of TNFα-inhibitors to induce both, clinically relevant lupus like disease and a high rate of seroconversion towards a lupus like antibody profile in a substantial proportion of patients. Our prospective study thus substantiates the hypothesis that these phenomena represent a systematic effect of TNFα-inhibitors, and that their incidence is higher than assumed by estimates based upon case reports.


Disclosure:

S. J. Winkelmann,
None;

R. A. Zeuner,
None;

D. Schuldt,
None;

J. Bethge,
None;

U. Mrowietz,
None;

M. Laudes,
None;

S. Schreiber,
None;

J. Schroeder,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-clinical-and-serological-lupus-like-disease-during-anti-tnf%ce%b1-treatment-a-two-year-prospective-study-in-an-interdisciplinary-patient-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.